TROGARZO (ibalizumab-uiyk)

OFFICE ADMINISTRATION

Indications for Prior Authorization:

  • Treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen, to be used in combination with other antiretroviral(s)

Patients must meet the following criteria for the indication(s) above:

  • Patients are 18 years of age or older, AND
  • Diagnosis of multidrug resistant HIV-1 infection, AND
  • Prescribed by or in consultation with an ID or HIV specialist, AND
  • Documentation of resistance to at least 1 antiretroviral (ARV) drug from each of the 4 classes (NRTI, NNRTI, PI, INSTI), unless contraindicated, AND
  • Failure of Fuzeon, unless resistant, contraindicated, or adverse effects are experienced, AND
  • Failure of Selzentry, if CCR5-tropic, unless resistant, contraindicated, or adverse effects are experienced, AND
  • Current HIV RNA viral load (within the past 30 days) of greater than or equal to 200 copies/mL, AND
  • Trogarzo is prescribed concurrently with additional antiretroviral agent(s), AND
  • Dose is no greater than 2,000mg (10 vials) IV loading dose and/or 800mg (4 vials) IV every 14 days

Dosing:

  • Loading dose: 2,000mg once
  • Maintenance dose: 800mg every 2 weeks

Approval:

  • 6 months

Last review date: April 30, 2019

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone